Sesen Bio Announces Commercial Launch Readiness Progress as the Company Approaches the Potential Approval and Launch of Vicineum

Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced the expansion of its leadership team with the appointment of experienced commercial industry leader, Lisa LaMond, as Vice President, Sales and Corporate Systems. The Company also announced its engagement of leading contract sales organization (CSO), Syneos Health, for field sales support and execution in the US for Vicineum.

Lisa LaMond brings invaluable experience in commercial pharmaceuticals to her role as Vice President, Sales and Corporate Systems. Prior to joining Sesen Bio, Ms. LaMond spent her career at Merck & Co. Inc. where she developed a diverse skillset across key commercial functions, as well as a deep understanding of the evolving healthcare environment and customer landscapes. Early in her Merck career, Ms. LaMond led large organizations and launched several innovative, FDA-approved products and a number of new initiatives that transformed the growth and strength of diverse geographical markets. She also held various leadership positions in sales, launch strategy, marketing, account management, risk management, and policy. At every level, she excelled at building new capabilities as well as developing strategy and priorities to drive execution for commercial success. Ms. LaMond holds a Bachelor of Science degree from California State University in Long Beach, CA, and earned her Masters of Business Administration from University of Redlands.

“I am delighted to welcome Lisa to the Sesen Bio senior leadership team,” said Dr. Thomas Cannell, president and chief executive officer of Sesen Bio. “Lisa’s many accomplishments over her career embody our mission to save and improve the lives of patients, and her extensive commercial experience will be critical in the development and oversight of our sales strategy and execution.”

Syneos Health has deep expertise in Urology and Uro-oncology with specific experience supporting first product launches in biopharmaceutical organizations. Syneos Health will provide comprehensive support for the sales organization including sales force logistics, hiring and deployment of key talent and sales force operations. The sales force will include 35 sales representatives across four regions to target approximately 2,000 high prescribers of BCG.